#United States #New York #Skincare #Amorepacific #IOPE

IOPE Debuts in the U.S. Market

On March 2, 2026, IOPE, a pioneering clinical-grade skincare brand hailing from Amorepacific, marked its official entry into the U.S. market, showcasing its commitment to advancing Korean skincare innovation. Known for its cutting-edge anti-aging products, IOPE is celebrated for its rigorous scientific backing and clinical focus. This launch comes three decades after the brand's establishment and aligns with its goal to offer targeted skincare solutions that deliver measurable results.

Under the leadership of Giovanni Valentini, the CEO of Amorepacific North America, IOPE's U.S. debut is a significant milestone that reflects the growing demand among consumers for products that are both clinically proven and effective. Valenti expressed excitement, stating, “We are thrilled to bring IOPE to the U.S. after decades of unparalleled performance in Korea.” In a saturated skincare landscape, the brand aims to meet the needs of discerning consumers who increasingly prioritize the efficacy and transparency of skincare solutions.

Unveiling Innovative Formulations

IOPE's product range available at launch includes nine targeted solutions that feature innovative technologies and active ingredients. Prominent among these are the XMD, Retinol RX™, and PDRN Caffeine collections. Each product is finely tuned to address common skin concerns such as texture, firmness, brightness, and overall skin vitality, setting new standards for at-home skincare performance.

Highlighted Products

1. XMD Stem III Clinical Recovery Serum ($59): This high-performance serum draws inspiration from Korea's viral professional PDRN treatments. It promises noticeable results in key skin metrics including elasticity and texture enhancement, thanks to a powerful formula that contains 92.3% PDRN H.A.™ Liposome Complex.

2. Retinol RX™ 2% Reti-jection™ Serum ($57): Leveraging a proprietary retinoid complex, this serum is designed to optimize effectiveness while minimizing irritation, paving the way for smoother skin and reduced appearance of wrinkles and pores.

3. Pricing Structure: IOPE's products are priced competitively, starting from $6.50 for a single sheet mask to $69 for the XMD Stem III Clinical Recovery Cream, ensuring accessibility to a broad audience.

Availability and Future Plans

IOPE's products officially launched on Sephora's website on the day of the announcement, with availability set to extend to physical Sephora locations nationwide by March 13, 2026. The brand's entry into the U.S. market marks a new chapter for Amorepacific, as it continues to build on its reputation as a leading figure in the global beauty industry. Established in 1945, Amorepacific has been at the forefront of innovation in skincare, makeup, and wellness, shaping the future of K-beauty with a focus on bio-driven and longevity-focused technology.

With its profound commitment to research and development, IOPE stands poised to meet the evolving needs of consumers while maintaining its position as a leader in the Korean skincare market. The brand not only brings advanced formulations that are deeply rooted in clinical research but also a promise of professionalism and quality that consumers can trust.

Conclusion

In a market where authenticity and proven results are critical, IOPE sets a high bar with its clinical-grade offerings. The introduction of this brand into the U.S. market signals a significant evolution in the American skincare landscape, where high-quality, science-backed products are becoming increasingly sought after. As consumers become more educated about their skincare choices, brands like IOPE represent the future of beauty—one where effectiveness and innovation are at the forefront of consumer priorities.